Partners to host global AI-enabled medical device innovation forum
Vyome Holdings, Inc. (Nasdaq: HIND) and Embryyo Technologies of Pune-Deleware have signed an MoU (Memorandum of Understanding) to jointly pursue the global AI-enabled medical device market.
The partnership will combine Vyome’s healthcare industry experience and resources with Embryyo’s medical technology capabilities to potentially productize and commercialize smart medical devices that can transform the standard-of-care in disease management and treatment.
“Vyome’s vision is to partner with the smartest talent tackling the biggest healthcare markets along the US-India corridor and across our three pillars of pharma, AI, and medical devices. AI-enabled medical devices represent a large opportunity and the Embryyo team – helmed by Indian Institutes of Technology (IIT) alums – has been working in this sector for a decade,” said Krishna Gupta, Chairman of Vyome Holdings.
“We will be working with them to identify the specific initiatives on which we will partner,” Gupta added on 21 Aug.
“We are currently developing a portfolio of transformative medical devices spanning interventional oncology, surgery, wearables, and drug delivery, and Vyome’s access to global capital markets and the US healthcare ecosystem will accelerate our mission to push the frontiers of medicine and elevate standards of care in healthcare globally,” said Nishant Kumar, Co-Founder and CEO of Embryyo Technologies.
“We are excited about this partnership with Vyome as we have a shared vision.”
As part of this partnership, Vyome and Embryyo will host a global AI-enabled medical device innovation forum for companies along the US-India corridor. The MoU is non-binding and may be subject to other conditions.
Embryyo is a medical device innovation studio which specializes in unmet clinical need discovery and validation, ideation, IP creation, early-stage technology de-risking and medical device product development. Over the years, Embryyo has worked with a diverse global clientele including med-tech MNC’s, inventive clinicians, philanthropic institutions, category leading manufacturers and funded startups, helping them identify, invent and realize first-of-its-kind medical devices. The company has also created a strong internal pipeline of early-stage med-tech IP assets which we are now outlicensing and commercialising through global partners and collaborators. Fiinews.com
